{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:57:49Z","timestamp":1785491869774,"version":"3.56.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Viral Hepatitis Care Network"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028420","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028420","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimal hepatitis C virus (HCV) screening is required to prevent transmission and progression to advanced liver disease and to meet global elimination targets. While administrative health data can highlight trends in testing and treatment, additional information is required to understand barriers in the care cascade. We conducted a real-world analysis documenting the care cascade and the effectiveness of HCV antibody (Ab) screening modalities across different community and clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a cross-sectional study of individuals who completed HCV Ab testing at participating centers in Ontario, Canada, between May 2010 and June 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 61 605 individuals tested, the prevalence of HCV Ab was 13.6% and highest among individuals aged 35\u201344 years (23.2%) and individuals tested at addiction clinics (41.0%). Among those with an HCV Ab\u2013positive result, 79.7% ever completed RNA testing of whom 57.3% were RNA positive. Among those with an RNA-positive result, 65.0% attended a follow-up appointment. Among those who attended their appointment, 94.0% initiated treatment (61.1% of the RNA-positive), 77.4% of those who started had documented treatment completion (47.3% of the RNA-positive), and 59.6% of those who completed treatment had documented sustained virologic response 12 weeks after treatment (28.2% of the RNA-positive). The Ab testing modality was closely related to test setting, and primary care was the most effective at linkage to care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While there was some attrition from HCV Ab positivity to RNA testing, treatment initiation was higher compared with administrative data. These results highlight the benefits of multiple testing modalities and matching the optimal Ab testing modality to the setting, with strong pathways for linkage to care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag218","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:53:20Z","timestamp":1782388400000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1530-5950","authenticated-orcid":false,"given":"Grishma","family":"Hirode","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Capraru","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-2487","authenticated-orcid":false,"given":"Aaron","family":"Vanderhoff","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B","family":"Mendlowitz","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Wolfson-Stofko","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Center for Drug Use and HIV\/HCV Research (CDUHR), School of Global Public Health, NewYork University , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Karkada","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smookler","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mediongo-Abasi","family":"Usoro","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-3583","authenticated-orcid":false,"given":"Steven M","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Bates","sequence":"additional","affiliation":[{"name":"Emergency Department, Toronto Western Hospital, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mazzulli","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Microbiology, University Health Network\/Sinai Health System , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua V","family":"Juan","sequence":"additional","affiliation":[{"name":"Albany Medical Clinic Hepatology Division, , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Shah","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"William Osler Health System Academics, , Brampton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Erasmus MC University Medical Center , Rotterdam ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L A","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-9908","authenticated-orcid":false,"given":"Mia J","family":"Biondi","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"School of Nursing, York University , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease\/Viral Hepatitis Care Network (VIRCAN), University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026073105013275900_ofag218-B1","doi-asserted-by":"crossref","first-page":"e44103","DOI":"10.1371\/journal.pone.0044103","article-title":"The impact of infection on population health: results of the Ontario burden of infectious diseases study","volume":"7","author":"Kwong","year":"2012","journal-title":"PLoS One"},{"key":"2026073105013275900_ofag218-B2","volume-title":"Global Hepatitis Report 2017","author":"World Health Organization","year":"2017"},{"key":"2026073105013275900_ofag218-B3","volume-title":"Hepatitis C in Canada: 2019 surveillance data","author":"Public Health Agency of Canada","year":"2019"},{"key":"2026073105013275900_ofag218-B4","doi-asserted-by":"crossref","first-page":"E677","DOI":"10.1503\/cmaj.170453","article-title":"The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver","volume":"190","author":"Shah","year":"2018","journal-title":"Can Med Assoc J"},{"key":"2026073105013275900_ofag218-B5","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.1503\/cmaj.161521","article-title":"Recommendations on hepatitis C screening for adults","volume":"189","author":"Grad","year":"2017","journal-title":"Can Med Assoc J"},{"key":"2026073105013275900_ofag218-B6","first-page":"1","article-title":"CDC recommendations for hepatitis C screening among adults\u2014United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"Morb Mortal Wkly Rep"},{"key":"2026073105013275900_ofag218-B7","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/liv.14840","article-title":"Viral hepatitis C cascade of care: a population-level comparison of immigrant and long-term residents","volume":"41","author":"Yasseen","year":"2021","journal-title":"Liver Int"},{"key":"2026073105013275900_ofag218-B8","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/jvh.13529","article-title":"Care cascade of patients with hepatitis C and HIV identified by emergency department screening","volume":"28","author":"Cowan","year":"2021","journal-title":"J Viral Hepat"},{"key":"2026073105013275900_ofag218-B9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12879-017-2242-y","article-title":"A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada","volume":"17","author":"Greenaway","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2026073105013275900_ofag218-B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-016-3799-7","article-title":"Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction","volume":"32","author":"Wakeman","year":"2017","journal-title":"J Gen Intern Med"},{"key":"2026073105013275900_ofag218-B11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2893.2009.01080.x","article-title":"Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents","volume":"16","author":"Grebely","year":"2009","journal-title":"J Viral Hepat"},{"key":"2026073105013275900_ofag218-B12","author":"Canadian Network on Hepatitis C Blueprint Writing Committee and Working Groups"},{"key":"2026073105013275900_ofag218-B13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jhep.2018.05.017","article-title":"New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings","volume":"69","author":"Chevaliez","year":"2018","journal-title":"J Hepatol"},{"key":"2026073105013275900_ofag218-B14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/liv.15123","article-title":"Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening","volume":"42","author":"Koo","year":"2022","journal-title":"Liver Int"},{"key":"2026073105013275900_ofag218-B15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugpo.2019.05.012","article-title":"Point-of-care hepatitis C testing from needle and syringe programs: an Australian feasibility study","volume":"72","author":"Williams","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2026073105013275900_ofag218-B16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3138\/canlivj-2021-0036","article-title":"Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario","volume":"5","author":"Biondi","year":"2022","journal-title":"Can Liver J"},{"key":"2026073105013275900_ofag218-B17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2016.02.031","article-title":"Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada","volume":"64","author":"Jacka","year":"2016","journal-title":"J Hepatol"},{"key":"2026073105013275900_ofag218-B18","first-page":"517","article-title":"Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users\u2014New York, November 2004-April 2007","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"Morb Mortal Wkly Rep"},{"key":"2026073105013275900_ofag218-B19","first-page":"537","article-title":"Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002\u20132009","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"Morb Mortal Wkly Rep"},{"key":"2026073105013275900_ofag218-B20","first-page":"358","article-title":"Notes from the field: hepatitis C virus infections among young adults\u2013rural Wisconsin, 2010","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"Morb Mortal Wkly Rep"},{"key":"2026073105013275900_ofag218-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-11-1","article-title":"Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study","volume":"11","author":"Barocas","year":"2014","journal-title":"Harm Reduct J"},{"key":"2026073105013275900_ofag218-B22","first-page":"327","article-title":"Mutual mistrust in the medical care of drug users: the keys to the \u201cnarc\u201d cabinet","volume":"17","author":"Merrill","year":"2002","journal-title":"J Gen Intern Med"},{"key":"2026073105013275900_ofag218-B23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/add.14608","article-title":"Life after opioid-involved overdose: survivor narratives and their implications for ER\/ED interventions","volume":"114","author":"Elliott","year":"2019","journal-title":"Addiction"},{"key":"2026073105013275900_ofag218-B24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1353\/hpu.0.0088","article-title":"Social stigma and the dilemmas of providing care to substance users in a safety-net emergency department","volume":"19","author":"Henderson","year":"2008","journal-title":"J Health Care Poor Underserved"},{"key":"2026073105013275900_ofag218-B25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3109\/10826081003659543","article-title":"The role of physician and nurse attitudes in the health care of injecting drug users","volume":"45","author":"Brener","year":"2010","journal-title":"Subst Use Misuse"},{"key":"2026073105013275900_ofag218-B26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"Van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"2026073105013275900_ofag218-B27","volume-title":"Buprenorphine\/naloxone for opioid dependence: clinical practice guideline","author":"Handford","year":"2011"},{"key":"2026073105013275900_ofag218-B28","doi-asserted-by":"crossref","first-page":"101036","DOI":"10.1016\/j.pmedr.2019.101036","article-title":"Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system","volume":"17","author":"Tapp","year":"2020","journal-title":"Prev Med Reports"},{"key":"2026073105013275900_ofag218-B29","doi-asserted-by":"crossref","first-page":"e000084","DOI":"10.1136\/bmjoq-2017-000084","article-title":"Electronic medical record alert improves HCV testing for baby boomers in primary care setting: adults born during 1945\u20131965","volume":"6","author":"Al-hihi","year":"2017","journal-title":"BMJ Open Qual"},{"key":"2026073105013275900_ofag218-B30","doi-asserted-by":"crossref","first-page":"e0216459","DOI":"10.1371\/journal.pone.0216459","article-title":"Leveraging the electronic health record to eliminate hepatitis C: screening in a large integrated healthcare system","volume":"14","author":"Geboy","year":"2019","journal-title":"PLoS One"},{"key":"2026073105013275900_ofag218-B31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/MLR.0000000000000715","article-title":"An electronic health record\u2013based intervention to promote hepatitis C virus testing among adults born between 1945 and 1965","volume":"55","author":"Federman","year":"2017","journal-title":"Med Care"},{"key":"2026073105013275900_ofag218-B32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2991\/jegh.k.200117.002","article-title":"Efficacy of DAAs in the treatment of chronic HCV: real-world data from the private health-care sector of the Kingdom of Saudi Arabia","volume":"10","author":"Hashim","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"2026073105013275900_ofag218-B33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/hep4.1826","article-title":"High effectiveness of broad access direct-acting antiviral therapy for hepatitis C in an Australian real-world cohort: the REACH-C study","volume":"6","author":"Yee","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026073105013275900_ofag218-B34","doi-asserted-by":"crossref","first-page":"e0191184","DOI":"10.1371\/journal.pone.0191184","article-title":"Population-based estimate of hepatitis C virus prevalence in Ontario, Canada","volume":"13","author":"Bolotin","year":"2018","journal-title":"PLoS One"},{"key":"2026073105013275900_ofag218-B35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1155\/2008\/173153","article-title":"The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004","volume":"22","author":"Myers","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"2026073105013275900_ofag218-B36","first-page":"3","article-title":"Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey","volume":"24","author":"Rotermann","year":"2013","journal-title":"Heal Rep"},{"key":"2026073105013275900_ofag218-B37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1155\/2014\/317623","article-title":"Burden of disease and cost of chronic hepatitis C infection in Canada","volume":"28","author":"Myers","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2026073105013275900_ofag218-B38","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.9778\/cmajo.20130087","article-title":"Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis","volume":"2","author":"Schanzer","year":"2014","journal-title":"CMAJ Open"},{"key":"2026073105013275900_ofag218-B39","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cgh.2018.08.080","article-title":"Cost effectiveness of universal screening for hepatitis C virus infection in the era of direct-acting, pangenotypic treatment regimens","volume":"17","author":"Eckman","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026073105013275900_ofag218-B40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","article-title":"Assessing the cost-effectiveness of hepatitis C screening strategies in France","volume":"69","author":"Deuffic-Burban","year":"2018","journal-title":"J Hepatol"},{"key":"2026073105013275900_ofag218-B41","first-page":"101000","article-title":"Universal screening for HCV infection in China: an effectiveness and cost-effectiveness analysis","volume":"6","author":"Zhou","year":"2024","journal-title":"JHEP Rep Innov Hepatol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag218\/68665013\/ofag218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag218\/68665013\/ofag218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:01:44Z","timestamp":1785488504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag218\/8722910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag218","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ofag218"}}